http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 29 Oct 2025 07:00:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/NLS+Pharmaceutics+and+Kadimastem+Highlight+Continued+BIRD+Foundation+Support+for+ITOL-102+Diabetes+Program+Following+Merger/25516662.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location></span>, <span class="legendSpanClass"><chron>Oct. 29, 2025</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.nlspharma.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NLSP" idsrc="xmltag.org" >NLS Pharmaceutics Ltd</span></a>. (Nasdaq: NLSP) ("NLS" or the "Company"), a biopharmaceutical company focused on developing innovative therapies for central nervous system and neurodegenerative disorders, and <a target="_blank" href="http://www.kadimastem.com/" target="_blank" rel="nofollow"><span value="TelAviv:KDST" idsrc="xmltag.org" >Kadimastem Ltd.</span></a> (TASE: KDST) ("<span value="TelAviv:KDST" idsrc="xmltag.org" >Kadimastem</span>"), a clinical-stage cell therapy company developing treatments http://www.streetinsider.com/Press+Releases/NLS+Pharmaceutics+and+Kadimastem+Highlight+Continued+BIRD+Foundation+Support+for+ITOL-102+Diabetes+Program+Following+Merger/25516662.html Wed, 29 Oct 2025 07:00:00 -0500 KDST NLSP O.13800188 O.23415075 http://www.streetinsider.com/Press+Releases/NLS+Pharmaceutics+and+Kadimastem+Highlight+Continued+BIRD+Foundation+Support+for+ITOL-102+Diabetes+Program+Following+Merger/25516662.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location></span>, <span class="legendSpanClass"><chron>Oct. 29, 2025</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.nlspharma.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NLSP" idsrc="xmltag.org" >NLS Pharmaceutics Ltd</span></a>. (Nasdaq: NLSP) ("NLS" or the "Company"), a biopharmaceutical company focused on developing innovative therapies for central nervous system and neurodegenerative disorders, and <a target="_blank" href="http://www.kadimastem.com/" target="_blank" rel="nofollow"><span value="TelAviv:KDST" idsrc="xmltag.org" >Kadimastem Ltd.</span></a> (TASE: KDST) ("<span value="TelAviv:KDST" idsrc="xmltag.org" >Kadimastem</span>"), a clinical-stage cell therapy company developing treatments http://www.streetinsider.com/Press+Releases/NLS+Pharmaceutics+and+Kadimastem+Highlight+Continued+BIRD+Foundation+Support+for+ITOL-102+Diabetes+Program+Following+Merger/25516662.html Wed, 29 Oct 2025 07:00:00 -0500 KDST NLSP O.13800188 O.23415075 http://www.streetinsider.com/Press+Releases/NLS+Pharmaceutics+and+Kadimastem+Highlight+Continued+BIRD+Foundation+Support+for+ITOL-102+Diabetes+Program+Following+Merger/25516662.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location></span>, <span class="legendSpanClass"><chron>Oct. 29, 2025</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.nlspharma.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NLSP" idsrc="xmltag.org" >NLS Pharmaceutics Ltd</span></a>. (Nasdaq: NLSP) ("NLS" or the "Company"), a biopharmaceutical company focused on developing innovative therapies for central nervous system and neurodegenerative disorders, and <a target="_blank" href="http://www.kadimastem.com/" target="_blank" rel="nofollow"><span value="TelAviv:KDST" idsrc="xmltag.org" >Kadimastem Ltd.</span></a> (TASE: KDST) ("<span value="TelAviv:KDST" idsrc="xmltag.org" >Kadimastem</span>"), a clinical-stage cell therapy company developing treatments http://www.streetinsider.com/Press+Releases/NLS+Pharmaceutics+and+Kadimastem+Highlight+Continued+BIRD+Foundation+Support+for+ITOL-102+Diabetes+Program+Following+Merger/25516662.html Wed, 29 Oct 2025 07:00:00 -0500 KDST NLSP O.13800188 O.23415075 http://www.streetinsider.com/Press+Releases/NLS+Pharmaceutics+and+Kadimastem+Highlight+Continued+BIRD+Foundation+Support+for+ITOL-102+Diabetes+Program+Following+Merger/25516662.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location></span>, <span class="legendSpanClass"><chron>Oct. 29, 2025</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.nlspharma.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NLSP" idsrc="xmltag.org" >NLS Pharmaceutics Ltd</span></a>. (Nasdaq: NLSP) ("NLS" or the "Company"), a biopharmaceutical company focused on developing innovative therapies for central nervous system and neurodegenerative disorders, and <a target="_blank" href="http://www.kadimastem.com/" target="_blank" rel="nofollow"><span value="TelAviv:KDST" idsrc="xmltag.org" >Kadimastem Ltd.</span></a> (TASE: KDST) ("<span value="TelAviv:KDST" idsrc="xmltag.org" >Kadimastem</span>"), a clinical-stage cell therapy company developing treatments http://www.streetinsider.com/Press+Releases/NLS+Pharmaceutics+and+Kadimastem+Highlight+Continued+BIRD+Foundation+Support+for+ITOL-102+Diabetes+Program+Following+Merger/25516662.html Wed, 29 Oct 2025 07:00:00 -0500 KDST NLSP O.13800188 O.23415075 http://www.streetinsider.com/PRNewswire/NLS+Pharmaceutics+and+Kadimastem+Highlight+Continued+BIRD+Foundation+Support+for+ITOL-102+Diabetes+Program+Following+Merger/25516662.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location></span>, <span class="legendSpanClass"><chron>Oct. 29, 2025</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.nlspharma.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NLSP" idsrc="xmltag.org" >NLS Pharmaceutics Ltd</span></a>. (Nasdaq: NLSP) ("NLS" or the "Company"), a biopharmaceutical company focused on developing innovative therapies for central nervous system and neurodegenerative disorders, and <a target="_blank" href="http://www.kadimastem.com/" target="_blank" rel="nofollow"><span value="TelAviv:KDST" idsrc="xmltag.org" >Kadimastem Ltd.</span></a> (TASE: KDST) ("<span value="TelAviv:KDST" idsrc="xmltag.org" >Kadimastem</span>"), a clinical-stage cell therapy company developing treatments http://www.streetinsider.com/PRNewswire/NLS+Pharmaceutics+and+Kadimastem+Highlight+Continued+BIRD+Foundation+Support+for+ITOL-102+Diabetes+Program+Following+Merger/25516662.html Wed, 29 Oct 2025 07:00:00 -0500 KDST NLSP O.13800188 O.23415075 http://www.streetinsider.com/PRNewswire/NLS+Pharmaceutics+and+Kadimastem+Highlight+Continued+BIRD+Foundation+Support+for+ITOL-102+Diabetes+Program+Following+Merger/25516662.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location></span>, <span class="legendSpanClass"><chron>Oct. 29, 2025</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.nlspharma.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NLSP" idsrc="xmltag.org" >NLS Pharmaceutics Ltd</span></a>. (Nasdaq: NLSP) ("NLS" or the "Company"), a biopharmaceutical company focused on developing innovative therapies for central nervous system and neurodegenerative disorders, and <a target="_blank" href="http://www.kadimastem.com/" target="_blank" rel="nofollow"><span value="TelAviv:KDST" idsrc="xmltag.org" >Kadimastem Ltd.</span></a> (TASE: KDST) ("<span value="TelAviv:KDST" idsrc="xmltag.org" >Kadimastem</span>"), a clinical-stage cell therapy company developing treatments http://www.streetinsider.com/PRNewswire/NLS+Pharmaceutics+and+Kadimastem+Highlight+Continued+BIRD+Foundation+Support+for+ITOL-102+Diabetes+Program+Following+Merger/25516662.html Wed, 29 Oct 2025 07:00:00 -0500 KDST NLSP O.13800188 O.23415075 http://www.streetinsider.com/PRNewswire/NLS+Pharmaceutics+and+Kadimastem+Highlight+Continued+BIRD+Foundation+Support+for+ITOL-102+Diabetes+Program+Following+Merger/25516662.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location></span>, <span class="legendSpanClass"><chron>Oct. 29, 2025</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.nlspharma.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NLSP" idsrc="xmltag.org" >NLS Pharmaceutics Ltd</span></a>. (Nasdaq: NLSP) ("NLS" or the "Company"), a biopharmaceutical company focused on developing innovative therapies for central nervous system and neurodegenerative disorders, and <a target="_blank" href="http://www.kadimastem.com/" target="_blank" rel="nofollow"><span value="TelAviv:KDST" idsrc="xmltag.org" >Kadimastem Ltd.</span></a> (TASE: KDST) ("<span value="TelAviv:KDST" idsrc="xmltag.org" >Kadimastem</span>"), a clinical-stage cell therapy company developing treatments http://www.streetinsider.com/PRNewswire/NLS+Pharmaceutics+and+Kadimastem+Highlight+Continued+BIRD+Foundation+Support+for+ITOL-102+Diabetes+Program+Following+Merger/25516662.html Wed, 29 Oct 2025 07:00:00 -0500 KDST NLSP O.13800188 O.23415075 http://www.streetinsider.com/PRNewswire/NLS+Pharmaceutics+and+Kadimastem+Highlight+Continued+BIRD+Foundation+Support+for+ITOL-102+Diabetes+Program+Following+Merger/25516662.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location></span>, <span class="legendSpanClass"><chron>Oct. 29, 2025</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.nlspharma.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NLSP" idsrc="xmltag.org" >NLS Pharmaceutics Ltd</span></a>. (Nasdaq: NLSP) ("NLS" or the "Company"), a biopharmaceutical company focused on developing innovative therapies for central nervous system and neurodegenerative disorders, and <a target="_blank" href="http://www.kadimastem.com/" target="_blank" rel="nofollow"><span value="TelAviv:KDST" idsrc="xmltag.org" >Kadimastem Ltd.</span></a> (TASE: KDST) ("<span value="TelAviv:KDST" idsrc="xmltag.org" >Kadimastem</span>"), a clinical-stage cell therapy company developing treatments http://www.streetinsider.com/PRNewswire/NLS+Pharmaceutics+and+Kadimastem+Highlight+Continued+BIRD+Foundation+Support+for+ITOL-102+Diabetes+Program+Following+Merger/25516662.html Wed, 29 Oct 2025 07:00:00 -0500 KDST NLSP O.13800188 O.23415075 http://www.streetinsider.com/Stock+Splits/NLS+Pharmaceutics+announces+reverse+stock+split+ahead+of+Kadimastem+merger/25515863.html <p>NLS Pharmaceutics Ltd. (NASDAQ: NLSP) announced a 1-for-10 reverse stock split effective October 30, 2025, in connection with its proposed merger with Kadimastem Ltd. (TASE: KDST).</p> <p>The company's shares will begin trading on the Nasdaq Capital Market on a post-split basis at market open on October 31, 2025, under the new ticker symbol "NCEL" and company name NewcelX Ltd., following the anticipated merger closing.</p> <p>The reverse split will affect all outstanding common shares with a par value of CHF 0.03 per share. The new CUSIP number for the shares following the merger and reverse split will be H5835A109. A notice of the http://www.streetinsider.com/Stock+Splits/NLS+Pharmaceutics+announces+reverse+stock+split+ahead+of+Kadimastem+merger/25515863.html Wed, 29 Oct 2025 06:00:25 -0500 KDST NLSP NLSPW O.13800188 O.23415075 http://www.streetinsider.com/Stock+Splits/NLS+Pharmaceutics+announces+reverse+stock+split+ahead+of+Kadimastem+merger/25515863.html <p>NLS Pharmaceutics Ltd. (NASDAQ: NLSP) announced a 1-for-10 reverse stock split effective October 30, 2025, in connection with its proposed merger with Kadimastem Ltd. (TASE: KDST).</p> <p>The company's shares will begin trading on the Nasdaq Capital Market on a post-split basis at market open on October 31, 2025, under the new ticker symbol "NCEL" and company name NewcelX Ltd., following the anticipated merger closing.</p> <p>The reverse split will affect all outstanding common shares with a par value of CHF 0.03 per share. The new CUSIP number for the shares following the merger and reverse split will be H5835A109. A notice of the http://www.streetinsider.com/Stock+Splits/NLS+Pharmaceutics+announces+reverse+stock+split+ahead+of+Kadimastem+merger/25515863.html Wed, 29 Oct 2025 06:00:25 -0500 KDST NLSP NLSPW O.13800188 O.23415075 http://www.streetinsider.com/Stock+Splits/NLS+Pharmaceutics+announces+reverse+stock+split+ahead+of+Kadimastem+merger/25515863.html <p>NLS Pharmaceutics Ltd. (NASDAQ: NLSP) announced a 1-for-10 reverse stock split effective October 30, 2025, in connection with its proposed merger with Kadimastem Ltd. (TASE: KDST).</p> <p>The company's shares will begin trading on the Nasdaq Capital Market on a post-split basis at market open on October 31, 2025, under the new ticker symbol "NCEL" and company name NewcelX Ltd., following the anticipated merger closing.</p> <p>The reverse split will affect all outstanding common shares with a par value of CHF 0.03 per share. The new CUSIP number for the shares following the merger and reverse split will be H5835A109. A notice of the http://www.streetinsider.com/Stock+Splits/NLS+Pharmaceutics+announces+reverse+stock+split+ahead+of+Kadimastem+merger/25515863.html Wed, 29 Oct 2025 06:00:25 -0500 KDST NLSP NLSPW O.13800188 O.23415075 http://www.streetinsider.com/Stock+Splits/NLS+Pharmaceutics+announces+reverse+stock+split+ahead+of+Kadimastem+merger/25515863.html <p>NLS Pharmaceutics Ltd. (NASDAQ: NLSP) announced a 1-for-10 reverse stock split effective October 30, 2025, in connection with its proposed merger with Kadimastem Ltd. (TASE: KDST).</p> <p>The company's shares will begin trading on the Nasdaq Capital Market on a post-split basis at market open on October 31, 2025, under the new ticker symbol "NCEL" and company name NewcelX Ltd., following the anticipated merger closing.</p> <p>The reverse split will affect all outstanding common shares with a par value of CHF 0.03 per share. The new CUSIP number for the shares following the merger and reverse split will be H5835A109. A notice of the http://www.streetinsider.com/Stock+Splits/NLS+Pharmaceutics+announces+reverse+stock+split+ahead+of+Kadimastem+merger/25515863.html Wed, 29 Oct 2025 06:00:25 -0500 KDST NLSP NLSPW O.13800188 O.23415075 http://www.streetinsider.com/Stock+Splits/NLS+Pharmaceutics+announces+reverse+stock+split+ahead+of+Kadimastem+merger/25515863.html <p>NLS Pharmaceutics Ltd. (NASDAQ: NLSP) announced a 1-for-10 reverse stock split effective October 30, 2025, in connection with its proposed merger with Kadimastem Ltd. (TASE: KDST).</p> <p>The company's shares will begin trading on the Nasdaq Capital Market on a post-split basis at market open on October 31, 2025, under the new ticker symbol "NCEL" and company name NewcelX Ltd., following the anticipated merger closing.</p> <p>The reverse split will affect all outstanding common shares with a par value of CHF 0.03 per share. The new CUSIP number for the shares following the merger and reverse split will be H5835A109. A notice of the http://www.streetinsider.com/Stock+Splits/NLS+Pharmaceutics+announces+reverse+stock+split+ahead+of+Kadimastem+merger/25515863.html Wed, 29 Oct 2025 06:00:25 -0500 KDST NLSP NLSPW O.13800188 O.23415075 http://www.streetinsider.com/Corporate+News/NLS+Pharmaceutics+announces+reverse+stock+split+ahead+of+Kadimastem+merger/25515863.html <p>NLS Pharmaceutics Ltd. (NASDAQ: NLSP) announced a 1-for-10 reverse stock split effective October 30, 2025, in connection with its proposed merger with Kadimastem Ltd. (TASE: KDST).</p> <p>The company's shares will begin trading on the Nasdaq Capital Market on a post-split basis at market open on October 31, 2025, under the new ticker symbol "NCEL" and company name NewcelX Ltd., following the anticipated merger closing.</p> <p>The reverse split will affect all outstanding common shares with a par value of CHF 0.03 per share. The new CUSIP number for the shares following the merger and reverse split will be H5835A109. A notice of the http://www.streetinsider.com/Corporate+News/NLS+Pharmaceutics+announces+reverse+stock+split+ahead+of+Kadimastem+merger/25515863.html Wed, 29 Oct 2025 06:00:25 -0500 KDST NLSP NLSPW O.13800188 O.23415075 http://www.streetinsider.com/Corporate+News/NLS+Pharmaceutics+announces+reverse+stock+split+ahead+of+Kadimastem+merger/25515863.html <p>NLS Pharmaceutics Ltd. (NASDAQ: NLSP) announced a 1-for-10 reverse stock split effective October 30, 2025, in connection with its proposed merger with Kadimastem Ltd. (TASE: KDST).</p> <p>The company's shares will begin trading on the Nasdaq Capital Market on a post-split basis at market open on October 31, 2025, under the new ticker symbol "NCEL" and company name NewcelX Ltd., following the anticipated merger closing.</p> <p>The reverse split will affect all outstanding common shares with a par value of CHF 0.03 per share. The new CUSIP number for the shares following the merger and reverse split will be H5835A109. A notice of the http://www.streetinsider.com/Corporate+News/NLS+Pharmaceutics+announces+reverse+stock+split+ahead+of+Kadimastem+merger/25515863.html Wed, 29 Oct 2025 06:00:25 -0500 KDST NLSP NLSPW O.13800188 O.23415075 http://www.streetinsider.com/Corporate+News/NLS+Pharmaceutics+announces+reverse+stock+split+ahead+of+Kadimastem+merger/25515863.html <p>NLS Pharmaceutics Ltd. (NASDAQ: NLSP) announced a 1-for-10 reverse stock split effective October 30, 2025, in connection with its proposed merger with Kadimastem Ltd. (TASE: KDST).</p> <p>The company's shares will begin trading on the Nasdaq Capital Market on a post-split basis at market open on October 31, 2025, under the new ticker symbol "NCEL" and company name NewcelX Ltd., following the anticipated merger closing.</p> <p>The reverse split will affect all outstanding common shares with a par value of CHF 0.03 per share. The new CUSIP number for the shares following the merger and reverse split will be H5835A109. A notice of the http://www.streetinsider.com/Corporate+News/NLS+Pharmaceutics+announces+reverse+stock+split+ahead+of+Kadimastem+merger/25515863.html Wed, 29 Oct 2025 06:00:25 -0500 KDST NLSP NLSPW O.13800188 O.23415075 http://www.streetinsider.com/Corporate+News/NLS+Pharmaceutics+announces+reverse+stock+split+ahead+of+Kadimastem+merger/25515863.html <p>NLS Pharmaceutics Ltd. (NASDAQ: NLSP) announced a 1-for-10 reverse stock split effective October 30, 2025, in connection with its proposed merger with Kadimastem Ltd. (TASE: KDST).</p> <p>The company's shares will begin trading on the Nasdaq Capital Market on a post-split basis at market open on October 31, 2025, under the new ticker symbol "NCEL" and company name NewcelX Ltd., following the anticipated merger closing.</p> <p>The reverse split will affect all outstanding common shares with a par value of CHF 0.03 per share. The new CUSIP number for the shares following the merger and reverse split will be H5835A109. A notice of the http://www.streetinsider.com/Corporate+News/NLS+Pharmaceutics+announces+reverse+stock+split+ahead+of+Kadimastem+merger/25515863.html Wed, 29 Oct 2025 06:00:25 -0500 KDST NLSP NLSPW O.13800188 O.23415075 http://www.streetinsider.com/Corporate+News/NLS+Pharmaceutics+announces+reverse+stock+split+ahead+of+Kadimastem+merger/25515863.html <p>NLS Pharmaceutics Ltd. (NASDAQ: NLSP) announced a 1-for-10 reverse stock split effective October 30, 2025, in connection with its proposed merger with Kadimastem Ltd. (TASE: KDST).</p> <p>The company's shares will begin trading on the Nasdaq Capital Market on a post-split basis at market open on October 31, 2025, under the new ticker symbol "NCEL" and company name NewcelX Ltd., following the anticipated merger closing.</p> <p>The reverse split will affect all outstanding common shares with a par value of CHF 0.03 per share. The new CUSIP number for the shares following the merger and reverse split will be H5835A109. A notice of the http://www.streetinsider.com/Corporate+News/NLS+Pharmaceutics+announces+reverse+stock+split+ahead+of+Kadimastem+merger/25515863.html Wed, 29 Oct 2025 06:00:25 -0500 KDST NLSP NLSPW O.13800188 O.23415075 http://www.streetinsider.com/Press+Releases/NLS+Pharmaceutics+Ltd.+Announces+1-for-10+Reverse+Share+Split+and+Name+Change+in+Connection+with+Proposed+Merger+with+Kadimastem/25515851.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location></span>, <span class="legendSpanClass"><chron>Oct. 29, 2025</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.nlspharma.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NLSP" idsrc="xmltag.org" >NLS Pharmaceutics Ltd.</span></a> (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it intends to effect a reverse share split of the Company's http://www.streetinsider.com/Press+Releases/NLS+Pharmaceutics+Ltd.+Announces+1-for-10+Reverse+Share+Split+and+Name+Change+in+Connection+with+Proposed+Merger+with+Kadimastem/25515851.html Wed, 29 Oct 2025 06:00:00 -0500 KDST NLSP NLSPW NLSPW O.13800188 O.23415075 http://www.streetinsider.com/Press+Releases/NLS+Pharmaceutics+Ltd.+Announces+1-for-10+Reverse+Share+Split+and+Name+Change+in+Connection+with+Proposed+Merger+with+Kadimastem/25515851.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location></span>, <span class="legendSpanClass"><chron>Oct. 29, 2025</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.nlspharma.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NLSP" idsrc="xmltag.org" >NLS Pharmaceutics Ltd.</span></a> (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it intends to effect a reverse share split of the Company's http://www.streetinsider.com/Press+Releases/NLS+Pharmaceutics+Ltd.+Announces+1-for-10+Reverse+Share+Split+and+Name+Change+in+Connection+with+Proposed+Merger+with+Kadimastem/25515851.html Wed, 29 Oct 2025 06:00:00 -0500 KDST NLSP NLSPW NLSPW O.13800188 O.23415075 http://www.streetinsider.com/Press+Releases/NLS+Pharmaceutics+Ltd.+Announces+1-for-10+Reverse+Share+Split+and+Name+Change+in+Connection+with+Proposed+Merger+with+Kadimastem/25515851.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location></span>, <span class="legendSpanClass"><chron>Oct. 29, 2025</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.nlspharma.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NLSP" idsrc="xmltag.org" >NLS Pharmaceutics Ltd.</span></a> (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it intends to effect a reverse share split of the Company's http://www.streetinsider.com/Press+Releases/NLS+Pharmaceutics+Ltd.+Announces+1-for-10+Reverse+Share+Split+and+Name+Change+in+Connection+with+Proposed+Merger+with+Kadimastem/25515851.html Wed, 29 Oct 2025 06:00:00 -0500 KDST NLSP NLSPW NLSPW O.13800188 O.23415075 http://www.streetinsider.com/Press+Releases/NLS+Pharmaceutics+Ltd.+Announces+1-for-10+Reverse+Share+Split+and+Name+Change+in+Connection+with+Proposed+Merger+with+Kadimastem/25515851.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location></span>, <span class="legendSpanClass"><chron>Oct. 29, 2025</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.nlspharma.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NLSP" idsrc="xmltag.org" >NLS Pharmaceutics Ltd.</span></a> (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it intends to effect a reverse share split of the Company's http://www.streetinsider.com/Press+Releases/NLS+Pharmaceutics+Ltd.+Announces+1-for-10+Reverse+Share+Split+and+Name+Change+in+Connection+with+Proposed+Merger+with+Kadimastem/25515851.html Wed, 29 Oct 2025 06:00:00 -0500 KDST NLSP NLSPW NLSPW O.13800188 O.23415075 http://www.streetinsider.com/Press+Releases/NLS+Pharmaceutics+Ltd.+Announces+1-for-10+Reverse+Share+Split+and+Name+Change+in+Connection+with+Proposed+Merger+with+Kadimastem/25515851.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location></span>, <span class="legendSpanClass"><chron>Oct. 29, 2025</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.nlspharma.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NLSP" idsrc="xmltag.org" >NLS Pharmaceutics Ltd.</span></a> (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it intends to effect a reverse share split of the Company's http://www.streetinsider.com/Press+Releases/NLS+Pharmaceutics+Ltd.+Announces+1-for-10+Reverse+Share+Split+and+Name+Change+in+Connection+with+Proposed+Merger+with+Kadimastem/25515851.html Wed, 29 Oct 2025 06:00:00 -0500 KDST NLSP NLSPW NLSPW O.13800188 O.23415075 http://www.streetinsider.com/Press+Releases/NLS+Pharmaceutics+Ltd.+Announces+1-for-10+Reverse+Share+Split+and+Name+Change+in+Connection+with+Proposed+Merger+with+Kadimastem/25515851.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location></span>, <span class="legendSpanClass"><chron>Oct. 29, 2025</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.nlspharma.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NLSP" idsrc="xmltag.org" >NLS Pharmaceutics Ltd.</span></a> (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it intends to effect a reverse share split of the Company's http://www.streetinsider.com/Press+Releases/NLS+Pharmaceutics+Ltd.+Announces+1-for-10+Reverse+Share+Split+and+Name+Change+in+Connection+with+Proposed+Merger+with+Kadimastem/25515851.html Wed, 29 Oct 2025 06:00:00 -0500 KDST NLSP NLSPW NLSPW O.13800188 O.23415075 http://www.streetinsider.com/PRNewswire/NLS+Pharmaceutics+Ltd.+Announces+1-for-10+Reverse+Share+Split+and+Name+Change+in+Connection+with+Proposed+Merger+with+Kadimastem/25515851.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location></span>, <span class="legendSpanClass"><chron>Oct. 29, 2025</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.nlspharma.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NLSP" idsrc="xmltag.org" >NLS Pharmaceutics Ltd.</span></a> (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it intends to effect a reverse share split of the Company's http://www.streetinsider.com/PRNewswire/NLS+Pharmaceutics+Ltd.+Announces+1-for-10+Reverse+Share+Split+and+Name+Change+in+Connection+with+Proposed+Merger+with+Kadimastem/25515851.html Wed, 29 Oct 2025 06:00:00 -0500 KDST NLSP NLSPW NLSPW O.13800188 O.23415075